Pretreatment elevated mean corpuscular volume as an indicator for high risk esophageal second primary cancer in patients with head and neck cancer

Tsushima, Nayuta; Kano, Satoshi; Suzuki, Takayoshi; Hamada, Seijiro; Homma, Akihiro

Pretreatment elevated mean corpuscular volume as an indicator for high risk esophageal second primary cancer in patients with head and neck cancer

Tsushima, Nayuta; Kano, Satoshi; Suzuki, Takayoshi et al.

Auris nasus larynx, 2023, 50(3), 423-429

Permalink : https://hdl.handle.net/2115/92745

このアイテムのアクセス数:251件（2026-10-09 17:26 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
Auris Nasus Larynx 50 423-429	pdf	730 KB	153

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/92745
タイトル	Pretreatment elevated mean corpuscular volume as an indicator for high risk esophageal second primary cancer in patients with head and neck cancer
著者	Tsushima, Nayuta ; Kano, Satoshi ; Suzuki, Takayoshi ; Hamada, Seijiro ; Homma, Akihiro
e-Rad_Researcher 50547643 著者名 Tsushima, Nayuta
著者名 Kano, Satoshi
著者名 Suzuki, Takayoshi
著者名 Hamada, Seijiro
e-Rad_Researcher 30312359 著者名 Homma, Akihiro
言語	英語
キーワード	Head and neck cancer
	Second primary cancer
	Esophageal cancer
	Mean corpuscular volume
	Aldehyde dehydrogenase
	Field cancerization
発行日	2023-06
出版者	Elsevier
収録物名	Auris nasus larynx
巻(号)	50(3)
ページ	423-429
抄録	Objective: Esophageal cancer is the most common second primary cancer (SPC) in patients with head and neck cancer (HNC). Esophageal SPC has a negative impact on survival. Elevated mean corpuscular volume (MCV) is an accepted predictor of esophageal cancer risk. The aim of this study was to elucidate the usefulness of elevated MCV as an indicator of a high risk for esophageal SPC. Methods: We retrospectively reviewed the medical records of patients with oropharyngeal, hy-popharyngeal, and laryngeal squamous cell carcinoma who underwent chemoradiotherapy be-tween 2003 and 2012. We excluded patients younger than 20 years or who had received treat-ment for esophageal cancer and who had a histologically unproven lesion. Patients were divided into two groups according to their MCV. The cut-off for MCV was defined by receiver operating characteristics curve analysis. The primary endpoint was the cumulative incidence of esophageal SPC.Results: A total of 295 patients were included. The median follow-up period for surviving patients was 7.4 years and the optimal cut-off point was 99.0 fL. One hundred ninety-five patients (66%) had an MCV < 99.0 fL and 100 (34%) had an MCV > 99.0 fL. The 5-year cumulative incidence in patients with an MCV < 99.0 fL and > 99.0 fL was 8.7% and 27%, respectively. In the multivariate analysis, an MCV > 99.0 fL (HR = 2.2; 95%CI, 1.1-4.2) was an independent risk factor. Conclusion: MCV > 99.0 fL was found to be a risk factor for esophageal SPC. We, therefore, recommend that patients with an MCV > 99.0 fL should undergo intensive monitoring.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報	© 2022. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	0385-8146
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.anl.2022.09.009